Forgot your login?

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.

E-Mail:
Also, what is 4 + 9?

India's Bharat Serum and Vaccines to Repurpose Sepsis Drug for COVID-19, an Industrial Info Market Brief

Indian vaccine-maker Bharat Serums and Vaccines Limited (BSVL) said it has received approval from the Drug Controller General of India (DCGI) to conduct the Phase III clinical trial of Sepsis drug Ulinastatin on COVID-19 patients showing mild-to-moderate acute respiratory distress symptoms.

Ulinastatin is used in India, China and Japan in the treatment of severe sepsis and other critical clinical conditions such as acute pancreatitis. Clinical trials to evaluate efficacy of the drug are likely to commence soon in six hospitals across India, enrolling 120 patients. Results are expected to be available by December 2020.

Login or Register for Instant Access

Subscribe Now!

(All Fields Required)

IIR Logo Globe

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

×